Sweet syndrome following Moderna COVID-19 vaccine: A case report, AUG 2022.
This is the 9th case of SARS-CoV2 vaccine-induced Sweet's syndrome (3 Pfizer, 2 AstraZeneca, 2 Moderna, 1 Janssen, 1 Sinovac-CoronaVac).
"A 60-year-old male with a history of a traumatic skin burn on his back, a monoclonal gammopathy of undetermined significance and one episode of Sweet syndrome following upper respiratory tract infection presented to the emergency with a skin eruption with abrupt onset. He presented multiple, tender, indurated erythematous papules and plaques over his face, trunk, upper, and lower limbs (Figures 1–4). The eruption started 2 days after receiving his first dose of Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2 vaccine) by intramuscular injection. Interestingly, a year before, he had the same eruption following an upper respiratory tract infection. He was seen by a dermatologist who performed a skin biopsy and histopathology was consistent with a diagnosis of classic Sweet syndrome. At this moment, he did not have a COVID-19 screening test. A large workup was made at the time of this first episode of Sweet syndrome and permitted to identify a monoclonal gammopathy of undetermined significance." journals.sagepub.com/doi/fu...